65
Participants
Start Date
September 24, 2019
Primary Completion Date
January 17, 2023
Study Completion Date
February 15, 2023
HBM4003
Intravenous (IV) administration
Macquarie University, 2 Technology Place, Macquarie
St. George Private Hospital, 1 South Street, Kogarah
The Alfred Hospital, Commercial Road, Melbourne
Monash Health, Monash Medical Centre, 246 Clayton Road, Clayton
Peking University First Hospital, Chemotherapy Department, No. 15 cheniandian Hutong, Annei Street, Dongcheng District, Beijing
Cancer Hospital Chinese Academy of Medical Sciences, Oncology Department, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing
Xuzhou Central Hospital, Oncology Department, No. 199 Jiefang South Road, Quanshan District, Xuzhou
Yantai Yuhuangding Hospital, Urology Department, 8th Floor, No. 20 Donglu Road, Zhifu District, Yantai
Tianjin Medical University Cancer Institute and Hospital, Biotherapeutic Department, 17 / F, Block C, West Huan-Hu Rd., Ti Yuan Bei, Hexi District, Tianjin
Zhejiang Cancer Hospital, Department of Head and Neck Medicine for Rare Diseases, No. 1, Banshan Road, Gongshu District, Hangzhou
Zhenjiang Cancer Hospital, Department of Interventional Therapy, No. 1, Banshan Road, Gongshu District, Hangzhou
Hunan Cancer Hospital, Intervention Division, 83 Tongzipo Road, Yuelu District, Changsha
Hunan Cancer Hospital, Urology Department, 83 Tongzipo Road, Yuelu District, Changsha
Union Hospital affiliated to Tongji Medical College of HUST, Oncology Department, No. 1277 Jiefang Dadao, Wuhan
Henan Cancer Hospital, Oncology Department, No. 127 Dongming Road, Jinshui District, Zhengzhou
The Second People's Hospital of Yibin, Oncology Department, No. 268 South Bank Nanguang Road, Xuzhou District, Yibin
Queen Mary Hospital, Department of Medicine, 102 Pok Fu Lam Road, Hong Kong
Lead Sponsor
Harbour BioMed US, Inc.
INDUSTRY